How Analysts Feel About Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)?

September 30, 2018 - By William Brooks

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Logo

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Ratings Coverage

Among 2 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catabasis Pharmaceuticals had 2 analyst reports since April 19, 2018 according to SRatingsIntel. The company was maintained on Thursday, April 19 by Wedbush. Citigroup maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) on Friday, August 10 with “Buy” rating. Below is a list of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) latest ratings and price target changes.

10/08/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $2.5 New Target: $1.5 Maintain
19/04/2018 Broker: Wedbush Rating: Buy New Target: $6.0000 Maintain

The stock decreased 2.75% or $0.02 during the last trading session, reaching $0.8. About 569,115 shares traded. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has declined 44.83% since September 30, 2017 and is downtrending. It has underperformed by 60.45% the S&P500.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $56.83 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

More news for Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) were recently published by: Streetinsider.com, which released: “Catabasis Pharma (CATB) Commences hase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular …” on September 25, 2018. Seekingalpha.com‘s article titled: “Key events next week – healthcare” and published on September 28, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: